A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

Br J Haematol. 2026 May;208(5):1878-1884. doi: 10.1111/bjh.70434. Epub 2026 Mar 17.

Abstract

Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction. In an eight-patient subset, migration inhibitory factor (MIF) levels, naïve (CD62Lhi) T-cell and HLA-DRhi monocyte subsets each correlated with treatment response.

Keywords: autoimmune haemolytic anaemia; fostamatinib; immune cytopenias.

Publication types

  • Multicenter Study

MeSH terms

  • Aminopyridines
  • Anemia, Hemolytic, Autoimmune* / blood
  • Anemia, Hemolytic, Autoimmune* / drug therapy
  • Female
  • Humans
  • Morpholines
  • Oxazines* / administration & dosage
  • Oxazines* / adverse effects
  • Oxazines* / therapeutic use
  • Pyridines* / administration & dosage
  • Pyridines* / adverse effects
  • Pyridines* / therapeutic use
  • Pyrimidines
  • Retrospective Studies
  • Thrombocytopenia* / blood
  • Thrombocytopenia* / drug therapy
  • Treatment Outcome

Substances

  • Pyrimidines
  • fostamatinib
  • Pyridines
  • Aminopyridines
  • Morpholines
  • Oxazines

Supplementary concepts

  • Evans Syndrome